Northland says important clinical trials are showing early results

2022-07-08 0 By

E company news, northland announced today that an important clinical trial program has achieved initial results.One of the projects raised by the company, “Phase ⅱ A clinical trial of recombinant human thymosin β4 for injection for the indication of ischemic reperfusion injury in acute myocardial infarction”, has completed enrollment, follow-up and statistical analysis of data, and obtained the preliminary study results.According to the company, this project, as the first study with target indication patients as the observation object, has achieved the purpose of preliminary exploration of drug administration safety, effective dose range, evaluation index selection and other purposes, and provides a basis for follow-up research. Currently, the company is actively preparing to carry out the follow-up phase ⅱ B clinical trial.